PT-141, also known as bremelanotide, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. It acts as an agonist at melanocortin receptors, principally MC3R and MC4R.
An accidental discovery
PT-141 emerged from research on Melanotan II, a melanocortin agonist studied for its effects on pigmentation. Sexual arousal appeared as an unintended effect during that work, and PT-141 was subsequently developed as a metabolite of the parent compound.
Central rather than peripheral
The distinction that matters in the literature is mechanism. PDE5 inhibitors act peripherally, on vascular smooth muscle and blood flow. PT-141 does not.
Research describes activity within central nervous system pathways associated with sexual arousal, mediated through melanocortin receptor signalling in the hypothalamus. Studies note this as the reason its research profile differs from vasodilatory approaches: the pathway is upstream of the vascular response rather than part of it.
Reported adverse events
Nausea appears frequently in the clinical literature, along with transient blood-pressure changes and flushing. Nausea is the most commonly documented, and the literature associates it with dose.
Because melanocortin receptors are also involved in pigmentation, hyperpigmentation has been reported in studies involving repeated administration.
Handling and availability
Supplied as a lyophilised powder in a factory-sealed vial, stored at −20 °C and protected from light. Space Pep supplies PT-141 in Egypt in a 10 mg presentation. See the performance and vitality collection.
All products supplied by Space Pep are intended strictly for laboratory research purposes. They are not drugs, foods, cosmetics, or medical devices, and are not intended to diagnose, treat, cure, or prevent any disease.